Reports Q3 revenue $260K, consensus $285K. The company states, “There is a palpable level of excitement and activation energy coursing through our company as we prepare to submit our application for approval of our first molecular diagnostic test kit for clinical use, GraftAssureDx, to the FDA. We expect to begin selling the product next year after we achieve regulatory marketing authorization.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study
- Insight Molecular says kidney transplant patient achieved ‘immune reset’
- Insight Molecular Diagnostics Extends Executive Employment Agreement
- Insight Molecular Diagnostics announces attendance at two industry conferences
- Insight Molecular Diagnostics Approves Executive Salary Increases